Evaluation of the pharmacokinetic interaction between esomeprazole (40 mg) and acetylsalicylic acid (325 mg) in healthy volunteers

Int J Clin Pharmacol Ther. 2009 Sep;47(9):564-9. doi: 10.5414/cpp47564.

Abstract

Objective: To evaluate the effect of esomeprazole on the pharmacokinetics of low-dose acetylsalicylic acid (ASA) during repeated co-administration.

Methods: This was an open, randomized, 3-way crossover study in 55 healthy volunteers. Treatment periods comprised 5 days' oral esomeprazole (40 mg) or ASA (325 mg) alone, or in combination, separated by washout of >or= 13 days. The primary pharmacokinetic end points were steady-state area under the concentration-time curve (AUCtau) and observed maximum plasma concentration (Cmax) of ASA +/- esomeprazole.

Results: The estimates (90% confidence interval) of the geometric mean ratios for AUCtau and Cmax of ASA +/- esomeprazole were 1.04 (1.00 - 1.09) and 1.12 (1.03 - 1.22), respectively. Corresponding results for esomeprazole +/- ASA were 0.93 (0.89 - 0.98) and 0.96 (0.91 - 1.01), respectively. Administration of esomeprazole and ASA in combination was well tolerated.

Conclusions: There was no pharmacokinetic interaction between esomeprazole (40 mg) and ASA (325 mg) during repeated co-administration in healthy volunteers.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacokinetics*
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Anti-Ulcer Agents / adverse effects
  • Anti-Ulcer Agents / pharmacokinetics*
  • Anti-Ulcer Agents / pharmacology*
  • Area Under Curve
  • Aspirin / pharmacokinetics*
  • Aspirin / pharmacology*
  • Cross-Over Studies
  • Drug Interactions
  • Esomeprazole / adverse effects
  • Esomeprazole / pharmacokinetics*
  • Esomeprazole / pharmacology*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Young Adult

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Anti-Ulcer Agents
  • Esomeprazole
  • Aspirin